DE602004012152D1 - Verwendung von cystin oder cystein zur vorbeugung und behandlung von oxidativem stress hervorgerufen durch hämodialyse bei patienten mit chronischen nierenerkrankungen - Google Patents
Verwendung von cystin oder cystein zur vorbeugung und behandlung von oxidativem stress hervorgerufen durch hämodialyse bei patienten mit chronischen nierenerkrankungenInfo
- Publication number
- DE602004012152D1 DE602004012152D1 DE602004012152T DE602004012152T DE602004012152D1 DE 602004012152 D1 DE602004012152 D1 DE 602004012152D1 DE 602004012152 T DE602004012152 T DE 602004012152T DE 602004012152 T DE602004012152 T DE 602004012152T DE 602004012152 D1 DE602004012152 D1 DE 602004012152D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- cystine
- hemodialysis
- oxidative stress
- chronic kidney
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000020832 chronic kidney disease Diseases 0.000 title abstract 3
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 title abstract 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 title abstract 2
- 229960003067 cystine Drugs 0.000 title abstract 2
- 238000001631 haemodialysis Methods 0.000 title abstract 2
- 230000000322 hemodialysis Effects 0.000 title abstract 2
- 230000036542 oxidative stress Effects 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 208000028208 end stage renal disease Diseases 0.000 abstract 1
- 201000000523 end stage renal failure Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- External Artificial Organs (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Tires In General (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT002528A ITMI20032528A1 (it) | 2003-12-19 | 2003-12-19 | Uso di cistina o di cisteina per la prevenzione e il |
| ITMI20032528 | 2003-12-19 | ||
| PCT/EP2004/014359 WO2005058305A1 (en) | 2003-12-19 | 2004-12-16 | The use of cystine or cysteine for the prevention and treatment of oxidative stress caused by haemodialysis and of acute or chronic kidney diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE602004012152D1 true DE602004012152D1 (de) | 2008-04-10 |
| DE602004012152T2 DE602004012152T2 (de) | 2009-02-26 |
Family
ID=34685626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004012152T Active DE602004012152T2 (de) | 2003-12-19 | 2004-12-16 | Verwendung von cystin oder cystein zur vorbeugung und behandlung von oxidativem stress hervorgerufen durch hämodialyse bei patienten mit chronischen nierenerkrankungen |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8362079B2 (de) |
| EP (1) | EP1696901B1 (de) |
| JP (1) | JP5564159B2 (de) |
| AT (1) | ATE387195T1 (de) |
| CA (1) | CA2551043C (de) |
| DE (1) | DE602004012152T2 (de) |
| ES (1) | ES2300856T3 (de) |
| IT (1) | ITMI20032528A1 (de) |
| MX (1) | MXPA06006778A (de) |
| WO (1) | WO2005058305A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20060206A1 (it) * | 2006-04-10 | 2007-10-11 | Bio3 Res Srl | Composizione farmaceutica orale contenente cistina o cisteina con glutatione per la prevenzione ed il trattamento dello stress ossidativo da emodialisi e dispositivo medico di somministrazione |
| EP2313106B1 (de) * | 2008-07-18 | 2016-03-30 | A1M Pharma AB | Medizinische verwendung des radikalfängers und antioxidants alpha-1-mikroglobulin |
| UA116639C2 (uk) * | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| ES2521841B1 (es) * | 2013-05-08 | 2015-09-09 | Instituto De Investigación Sanitaria - Fundación Jiménez Díaz | Procedimiento de diagnóstico y pronóstico de la enfermedad renal crónica en un sujeto humano |
| JP6906807B2 (ja) | 2018-08-31 | 2021-07-21 | 一般社団法人クラインシュタイン医工学パースペクティブ | 透析装置 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5334617A (en) * | 1984-03-19 | 1994-08-02 | The Rockefeller University | Amino acids useful as inhibitors of the advanced glycosylation of proteins |
| DE3414491A1 (de) * | 1984-04-17 | 1985-10-24 | Hans Dr. 8202 Bad Aibling Dietl | L-aminosaeurengemische fuer die parenterale und orale anwendung bei nierenerkrankungen |
| DE3445253A1 (de) * | 1984-12-12 | 1986-06-26 | Dr. Madaus & Co, 5000 Köln | Nephrologisch-urologisches arzneimittel |
| JPH0610132B2 (ja) * | 1985-11-27 | 1994-02-09 | 千寿製薬株式会社 | 糖尿病性白内障治療薬 |
| JPH0667831B2 (ja) * | 1986-01-13 | 1994-08-31 | 森永乳業株式会社 | 肝物質合成機能障害改善用のアミノ酸組成物 |
| CA1339070C (en) * | 1989-01-26 | 1997-07-29 | Wulf Droge | Treatment of diseases associated with cysteine deficiency |
| JPH02212424A (ja) * | 1989-02-10 | 1990-08-23 | Toutoushiyu Seizo Kk | 肝障害抑制剤 |
| JP2534139B2 (ja) * | 1989-10-09 | 1996-09-11 | 株式会社大塚製薬工場 | 腎不全用経口アミノ酸製剤 |
| DE4343593C2 (de) * | 1993-12-21 | 1998-05-20 | Asta Medica Ag | Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz |
| US5576287A (en) * | 1994-04-29 | 1996-11-19 | Wake Forest University | Method for treating acute renal disease and failure |
| NZ527924A (en) * | 1999-01-29 | 2005-01-28 | Mars Uk Ltd | Antioxidant compositions and methods for companion animals |
| IT1312377B1 (it) * | 1999-03-05 | 2002-04-15 | Uni Ci S R L | Composizioni a base di acido tiottico, cisteina e/o n-acetil cisteinada utilizzarsi in preparazioni farmaceutiche, dietetiche e cosmetiche |
| IT1312086B1 (it) * | 1999-04-21 | 2002-04-04 | Zambon Spa | Uso della nac per la preparazione di un medicamento adatto allasomministrazione endovenosa per la prevenzione dello stress |
| AU5939901A (en) * | 2000-10-27 | 2002-05-06 | Nitromed Inc | Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| US20020137785A1 (en) * | 2001-03-26 | 2002-09-26 | George Kindness | Inflammatory mechanism modulator composition and methods with anti-asthmatic properties |
| FR2826868B1 (fr) * | 2001-07-04 | 2007-10-12 | Sanofi Synthelabo | Composition pour l'hygiene bucco-dentaire comprenant un vecteur d'ions fluorure et un agent antioxydant, ses utilisations notamment pour l'hygiene bucco-dentaire des sujets diabetiques |
-
2003
- 2003-12-19 IT IT002528A patent/ITMI20032528A1/it unknown
-
2004
- 2004-12-16 AT AT04803971T patent/ATE387195T1/de active
- 2004-12-16 MX MXPA06006778A patent/MXPA06006778A/es active IP Right Grant
- 2004-12-16 US US10/583,334 patent/US8362079B2/en not_active Expired - Fee Related
- 2004-12-16 JP JP2006544341A patent/JP5564159B2/ja not_active Expired - Fee Related
- 2004-12-16 EP EP04803971A patent/EP1696901B1/de not_active Not-in-force
- 2004-12-16 WO PCT/EP2004/014359 patent/WO2005058305A1/en active IP Right Grant
- 2004-12-16 ES ES04803971T patent/ES2300856T3/es active Active
- 2004-12-16 DE DE602004012152T patent/DE602004012152T2/de active Active
- 2004-12-16 CA CA2551043A patent/CA2551043C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP5564159B2 (ja) | 2014-07-30 |
| ATE387195T1 (de) | 2008-03-15 |
| EP1696901A1 (de) | 2006-09-06 |
| US20070270495A1 (en) | 2007-11-22 |
| DE602004012152T2 (de) | 2009-02-26 |
| MXPA06006778A (es) | 2007-01-26 |
| ES2300856T3 (es) | 2008-06-16 |
| ITMI20032528A1 (it) | 2005-06-20 |
| CA2551043C (en) | 2012-11-06 |
| WO2005058305A1 (en) | 2005-06-30 |
| CA2551043A1 (en) | 2005-06-30 |
| JP2007534646A (ja) | 2007-11-29 |
| EP1696901B1 (de) | 2008-02-27 |
| US8362079B2 (en) | 2013-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1113183T1 (el) | Χρηση νατριουριτικου πεπτιδιου για θεραπεια καρδιακης ανεπαρκειας | |
| HK1121074A1 (en) | Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione | |
| EA200700273A1 (ru) | Способ лечения гиперфосфатемии c использованием гидроксикарбоната лантана | |
| SG147444A1 (en) | Anti-ox40l antibodies | |
| MX2008004734A (es) | Composicion rica en leucina. | |
| BRPI0612840A8 (pt) | Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções | |
| NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
| DE60215787D1 (de) | Behandlung von typ ii diabetes mit dipeptidyl-peptidase-iv-hemmern | |
| DE602005014348D1 (de) | Medikament auf pflanzlicher basis zur behandlung von hepatitis c | |
| EA200801842A1 (ru) | Антитела против бета-амилоидного пептида | |
| EA200802213A1 (ru) | Способы лечения заболеваний крови | |
| ATE524190T1 (de) | Hemmung von cholera-toxinen durch galatooligosacchariden (gos) | |
| EA200601386A1 (ru) | ИММУНОГЛОБУЛИНЫ ПРОТИВ АНТИГЕНА EpCAM | |
| ATE551052T1 (de) | Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz | |
| DK1497330T3 (da) | Antagonister af faktor-VIII-interaktion med lav-densitets- lipoproteinreceptor-relateret protein | |
| CY1112620T1 (el) | Συνθεσεις οι οποιες περιλαμβανουν πεπτιδια βασικης πρωτεϊνης της μυελινης και ιατρικες χρησεις αυτων | |
| DE602004012152D1 (de) | Verwendung von cystin oder cystein zur vorbeugung und behandlung von oxidativem stress hervorgerufen durch hämodialyse bei patienten mit chronischen nierenerkrankungen | |
| EA200702336A1 (ru) | ПРИМЕНЕНИЕ 24-норУДХК | |
| BRPI0410761A (pt) | uso de leucina, e, composição para administração entérica a pacientes | |
| DE602006020838D1 (de) | Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum | |
| ME00489B (me) | NOVA SINERGIČKA KOMBINACIJA KOJA UKLJUČUJE ROFLUMILAST l FERMOTEROL | |
| DK1596879T3 (da) | Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis | |
| UA85548C2 (ru) | Применение водного экстракта листьев красного винограда для предупреждения перехода от клинически незначительных ранних стадий хронической венозной недостаточности к i, ii или iii стадии | |
| ATE412903T1 (de) | Diagnostik- und therapie- verfahren von mit c5a rezeptor verbundenen krankheiten | |
| EA200600989A1 (ru) | Применение габоксадола для лечения бессонницы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |